ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 27, 2023 -- Once-weekly tirzepatide provides substantial and clinically meaningful reductions in body weight in adults with obesity and type 2 diabetes, according to a study published online June 26 in the The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 23 to 26 in San Diego.
W. Timothy Garvey, M.D., from the UAB Diabetes Research Center at the University of Alabama at Birmingham, and colleagues examined the efficacy and safety of tirzepatide versus placebo for weight management for people with obesity and type 2 diabetes in a phase 3 trial conducted in seven countries. Adults with a body mass index of 27 kg/m2 or higher and glycated hemoglobin of 7 to 10 percent were randomly assigned to receive once-weekly, subcutaneous tirzepatide (10 or 15 mg) or placebo for 72 weeks (312, 311, and 315, respectively).
The researchers found that the least-squares mean change in bodyweight at week 72 was −12.8, −14.7, and −3.2 percent, respectively, with tirzepatide 10 mg and 15 mg, and placebo. Bodyweight reduction thresholds of 5 percent or higher were met by more participants treated with tirzepatide versus placebo (79 to 83 percent versus 32 percent). Gastrointestinal-related adverse events were the most frequent adverse events reported with tirzepatide, and included nausea, diarrhea, and vomiting; most were mild to moderate in severity, and few led to treatment discontinuation (<5 percent).
"We are encouraged by these weight loss and glycemic control results, especially as weight loss interventions are typically less effective in patients in diabetes," Garvey said in a statement.
Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study...
Sleep Restriction Tied to Negative Cognitive Effects in Teens With Overweight, Obesity
WEDNESDAY, May 22, 2024 -- Adolescents with overweight or obesity may be more vulnerable to negative cognitive effects following sleep restriction, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.